<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Shanghai Arch Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Shanghai Arch Psychiatry</journal-id><journal-id journal-id-type="publisher-id">SAP</journal-id><journal-title-group><journal-title>Shanghai Archives of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1002-0829</issn><publisher><publisher-name>Shanghai Municipal Bureau of Publishing</publisher-name><publisher-loc>Shanghai, China</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26549958</article-id><article-id pub-id-type="pmc">4621287</article-id><article-id pub-id-type="publisher-id">sap-27-04-220</article-id><article-id pub-id-type="doi">10.11919/j.issn.1002-0829.215055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Single-blind, randomized controlled trial of effectiveness of
Naikan therapy as an adjunctive treatment for schizophrenia
over a one-year follow-up period</article-title><trans-title-group xml:lang="zh"><trans-title>&#x05bf9;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x08f85;&#x052a9;&#x06cbb;&#x07597;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x07597;&#x06548;&#x07684;1&#x05e74;&#x0968f;&#x08bbf;&#x0ff1a;&#x04e00;&#x09879;&#x05355;&#x076f2;&#x03001;&#x0968f;&#x0673a;&#x05bf9;&#x07167;&#x07814;&#x07a76;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="bio" rid="d35e38">*</xref></contrib><contrib contrib-type="author"><name><surname>LI</surname><given-names>Chenhu</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>ZHAO</surname><given-names>Liyu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>ZHAN</surname><given-names>Guilai</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Shanghai Xuhui District Mental Health Center, Shanghai, China</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>correspondence: <email> li_chenhu@163.com</email> (Chenhu LI); </corresp></author-notes><pub-date pub-type="ppub"><day>25</day><month>8</month><year>2015</year></pub-date><volume>27</volume><issue>4</issue><fpage>220</fpage><lpage>227</lpage><history><date date-type="received"><day>11</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 by Editorial Department of the Shanghai Archives of Psychiatry</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p></license></permissions><abstract><sec id="s1"><title>Background</title><p>Current treatments for schizophrenia are often only partially effective.</p></sec><sec id="s2"><title>Aims</title><p>Assess the possible benefit of using adjunctive Naikan therapy, a cognitive approach based on self-reflection
that originated in Japan for the treatment of schizophrenia.</p></sec><sec id="s3"><title>Methods</title><p>After resolution of acute psychotic symptoms, 235 psychiatric inpatients with schizophrenia who
had a middle school education or higher were randomly assigned to a control group (n=112) that received
routine medication and inpatient rehabilitative treatment or an intervention group (n=123) that also
received adjunctive Naikan therapy for 2 hours daily, 5 days a week for 4 weeks. The patients were then
discharged and followed up for 12 months. The Positive and Negative Syndrome Scale (PANSS), Personal and
Social Performance scale (PSP), and Insight and Attitude Questionnaire (ITAQ) were used to assess patients at
enrollment, after the 1-month intervention, and after the 12-month follow-up. Evaluators were blind to the
group assignment of patients.</p></sec><sec id="s4"><title>Results</title><p> Only 13 (10.6%) of the intervention group participants relapsed over the 12-month follow-up, but 23
(20.5%) control group participants relapsed (X<sup>2</sup>=4.50, p=0.034). Using a modified intention-to-treat analysis
and a repeated measure analysis of variance, the PANSS, PSP, and ITAQ total scores all showed significantly
greater improvement over the 12-month follow-up in the Naikan group than in the control group. The drop in
mean chlorpromazine-equivalent dosage from enrollment to the end of follow-up was significantly different
in the intervention group but not in the control group, though the change in dosage over time between
groups was not statistically significant.</p></sec><sec id="s5"><title>Conclusions</title><p>This study provides robust support for the effectiveness of Naikan therapy as an adjunctive
treatment during the recovery period of schizophrenia. Compared to treatment as usually, adjunctive Naikan
therapy can sustain the improvement in psychotic symptoms achieved during acute treatment, improve
insight about the illness, enhance social functioning, and reduce relapse over a one-year follow-up period.
Further research of this treatment with larger and more diverse samples of patients with schizophrenia is
merited.</p></sec></abstract><trans-abstract xml:lang="zh"><sec><title>&#x080cc;&#x0666f;</title><p>&#x076ee;&#x0524d;&#x07684;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x06cbb;&#x07597;&#x05e38;&#x05e38;&#x053ea;&#x0662f;&#x090e8;&#x05206;&#x06709;&#x06548;&#x03002;</p></sec><sec><title>&#x076ee;&#x07684;</title><p>&#x08bc4;&#x04f30;&#x05728;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x07684;&#x06cbb;&#x07597;&#x04e2d;&#x04f7f;&#x07528;&#x08f85;&#x052a9;&#x06027;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x053ef;&#x080fd;&#x05e26;&#x06765;&#x07684;&#x076ca;&#x05904;&#x0ff0c;&#x08be5;&#x07597;&#x06cd5;&#x0662f;&#x04e00;&#x079cd;&#x06e90;&#x04e8e;&#x065e5;&#x0672c;&#x03001;&#x057fa;&#x04e8e;&#x05185;&#x07701;&#x07684;&#x08ba4;&#x077e5;&#x065b9;&#x06cd5;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x05728;&#x06025;&#x06027;&#x07cbe;&#x0795e;&#x075c5;&#x06027;&#x075c7;&#x072b6;&#x07f13;&#x089e3;&#x0540e;&#x0ff0c;235 &#x04f8b;&#x05177;&#x06709;&#x0521d;&#x04e2d;&#x04ee5;&#x04e0a;&#x05b66;&#x05386;&#x07684;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x04f4f;&#x09662;&#x060a3;&#x08005;&#x088ab;&#x0968f;&#x0673a;&#x05206;&#x04e3a;&#x05bf9;&#x07167;&#x07ec4; (n=112) &#x06216;&#x05e72;&#x09884;&#x07ec4; (n=123)&#x03002;&#x0524d;&#x08005;&#x063a5;&#x053d7;&#x05e38;&#x089c4;&#x0836f;&#x07269;&#x06cbb;&#x07597;&#x0548c;&#x04f4f;&#x09662;&#x05eb7;&#x0590d;&#x06cbb;&#x07597;&#x0ff0c;&#x0540e;&#x08005;&#x05728;&#x06b64;&#x057fa;&#x07840;&#x04e0a;&#x063a5;&#x053d7;&#x08f85;&#x052a9;&#x06027;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x0ff0c;&#x06bcf;&#x05929;2 &#x05c0f;&#x065f6;&#x0ff0c;&#x06bcf;&#x05468;5&#x05929;&#x0ff0c;&#x04e3a;&#x0671f;4&#x05468;&#x03002;&#x05bf9;&#x06240;&#x06709;&#x060a3;&#x08005;&#x05728;&#x051fa;&#x09662;&#x0540e;&#x08fdb;&#x0884c;12&#x04e2a;&#x06708;&#x07684;&#x0968f;&#x08bbf;&#x03002;&#x05728;&#x057fa;&#x07ebf;&#x03001;&#x05e72;&#x09884;1&#x04e2a;&#x06708;&#x0540e;&#x04ee5;&#x053ca;&#x0968f;&#x08bbf;12&#x04e2a;&#x06708;&#x0540e;&#x0ff0c;&#x091c7;&#x07528;&#x09633;&#x06027;&#x0548c;&#x09634;&#x06027;&#x075c7;&#x072b6;&#x091cf;&#x08868; (Positive and Negative Syndrome Scale, PANSS)&#x03001;&#x04e2a;&#x04eba;&#x0548c;&#x0793e;&#x04f1a;&#x0529f;&#x080fd;&#x091cf;&#x08868; (Personal and Social Performance scale, PSP) &#x04ee5;&#x053ca;&#x081ea;&#x077e5;&#x0529b;&#x04e0e;&#x06cbb;&#x07597;&#x06001;&#x05ea6;&#x095ee;&#x05377; (Insight and Attitude Questionnaire, ITAQ) &#x05206;&#x0522b;&#x05bf9;&#x060a3;&#x08005;&#x08fdb;&#x0884c;&#x08bc4;&#x04f30;&#x03002;&#x05bf9;&#x08bc4;&#x04f30;&#x08005;&#x04f7f;&#x07528;&#x076f2;&#x06cd5;&#x0ff0c;&#x09690;&#x07792;&#x060a3;&#x08005;&#x07684;&#x05206;&#x07ec4;&#x060c5;&#x051b5;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;12&#x04e2a;&#x06708;&#x07684;&#x0968f;&#x08bbf;&#x04e2d;&#x05e72;&#x09884;&#x07ec4;&#x053ea;&#x06709;13&#x04f8b; (10.6%) &#x0590d;&#x053d1;&#x0ff0c;&#x04f46;&#x0662f;&#x05bf9;&#x07167;&#x07ec4;&#x06709; 23 &#x04f8b; (20.5%) &#x0590d;&#x053d1; (X<sup>2</sup>=4.50, <italic>p</italic>=0.034)&#x03002;&#x04f7f;&#x07528;&#x04fee;&#x06b63;&#x07684;&#x0610f;&#x05411;&#x06cbb;&#x07597;&#x05206;&#x06790;&#x0548c;&#x091cd;&#x0590d;&#x06d4b;&#x091cf;&#x065b9;&#x05dee;&#x05206;&#x06790;&#x0ff0c;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x07ec4;&#x07684;PANSS&#x03001;PSP &#x0548c; ITAQ &#x0603b;&#x05206;&#x05747;&#x05728;12&#x04e2a;&#x06708;&#x07684;&#x0968f;&#x08bbf;&#x04e2d;&#x06bd4;&#x05bf9;&#x07167;&#x07ec4;&#x06709;&#x066f4;&#x0663e;&#x08457;&#x07684;&#x06539;&#x05584;&#x03002;&#x05c3d;&#x07ba1;&#x04e24;&#x07ec4;&#x04e4b;&#x095f4;&#x0836f;&#x07269;&#x05242;&#x091cf;&#x0ff08;&#x06c2f;&#x04e19;&#x055ea;&#x07b49;&#x06548;&#x05242;&#x091cf;&#x0ff09;&#x0968f;&#x065f6;&#x095f4;&#x053d8;&#x05316;&#x08d8b;&#x052bf;&#x07684;&#x05dee;&#x05f02;&#x05e76;&#x065e0;&#x07edf;&#x08ba1;&#x05b66;&#x0610f;&#x04e49;&#x0ff0c;&#x04f46;&#x04ece;&#x05165;&#x07ec4;&#x05230;&#x0968f;&#x08bbf;&#x07ec8;&#x070b9;&#x0ff0c;&#x05e72;&#x09884;&#x07ec4;&#x07684;&#x05e73;&#x05747;&#x05242;&#x091cf;&#x0663e;&#x08457;&#x051cf;&#x05c11;&#x0800c;&#x05bf9;&#x07167;&#x07ec4;&#x07684;&#x051cf;&#x05c11;&#x05728;&#x07edf;&#x08ba1;&#x05b66;&#x04e0a;&#x05e76;&#x04e0d;&#x0663e;&#x08457;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x0672c;&#x07814;&#x07a76;&#x06709;&#x0529b;&#x0652f;&#x06301;&#x04e86;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x04f5c;&#x04e3a;&#x08f85;&#x052a9;&#x06cbb;&#x07597;&#x05728;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x05eb7;&#x0590d;&#x0671f;&#x0662f;&#x06709;&#x06548;&#x07684;&#x03002;&#x076f8;&#x06bd4;&#x04e8e;&#x05e38;&#x089c4;&#x06cbb;&#x07597;&#x0ff0c;&#x08f85;&#x04ee5;&#x05185;&#x089c2;&#x07597;&#x06cd5;&#x053ef;&#x04ee5;&#x07ef4;&#x06301;&#x06025;&#x06027;&#x06cbb;&#x07597;&#x0671f;&#x095f4;&#x06240;&#x053d6;&#x05f97;&#x07684;&#x07cbe;&#x0795e;&#x075c5;&#x06027;&#x075c7;&#x072b6;&#x06539;&#x05584;&#x07684;&#x07597;&#x06548;&#x03001;&#x063d0;&#x09ad8;&#x05bf9;&#x075be;&#x075c5;&#x07684;&#x081ea;&#x077e5;&#x0529b;&#x03001;&#x063d0;&#x09ad8;&#x0793e;&#x04f1a;&#x0529f;&#x080fd;&#x0ff0c;&#x05e76;&#x05728;&#x04e00;&#x05e74;&#x07684;&#x0968f;&#x08bbf;&#x0671f;&#x05185;&#x051cf;&#x05c11;&#x0590d;&#x053d1;&#x03002;&#x08fd9;&#x0503c;&#x05f97;&#x06211;&#x04eec;&#x05728;&#x066f4;&#x05927;&#x03001;&#x066f4;&#x0591a;&#x06837;&#x05316;&#x07684;&#x07cbe;&#x0795e;&#x05206;&#x088c2;&#x075c7;&#x060a3;&#x08005;&#x06837;&#x0672c;&#x04e2d;&#x08fdb;&#x04e00;&#x06b65;&#x07814;&#x07a76;&#x08fd9;&#x079cd;&#x06cbb;&#x07597;&#x065b9;&#x06cd5;&#x03002;</p></sec><sec><title>&#x04e2d;&#x06587;&#x05168;&#x06587;</title><p>&#x0672c;&#x06587;&#x05168;&#x06587;&#x04e2d;&#x06587;&#x07248;&#x04ece;2015&#x05e74;10&#x06708;26&#x065e5;&#x08d77;&#x05728;<ext-link ext-link-type="doi" xlink:href="10.11919/j.issn.1002-0829.215055">htp://dx.doi.org/10.11919/j.issn.1002-0829.215055</ext-link>&#x053ef;&#x04f9b;&#x0514d;&#x08d39;&#x09605;&#x089c8;&#x04e0b;&#x08f7d;</p></sec></trans-abstract><kwd-group kwd-group-type="author-created"><kwd>Naikan therapy</kwd><kwd>schizophrenia</kwd><kwd>relapse</kwd><kwd>social functioning</kwd><kwd>randomized controlled trial</kwd><kwd>China</kwd></kwd-group><funding-group><funding-statement>None</funding-statement></funding-group></article-meta></front><body><sec id="s6"><label>1.</label><title>Background</title><p>
Schizophrenia, a chronic mental illness with frequent
episodes of severe psychotic symptoms, is a disabling
condition that seriously impairs social functioning
and usually has a poor prognosis. After the first
acute episode approximately 50% of patients have a
recurrence within one year and approximately 85%
of patients have a recurrence within 5 years.[<xref rid="B1" ref-type="bibr">1</xref>] This
high recurrence rate results in a substantial social
and financial burden for the individual, the family, 
and society at large. Other studies report that costs
incurred by individuals who relapse within one year of
their first episode are three- to four-fold higher than
those incurred by individuals who do not relapse.[<xref rid="B2" ref-type="bibr">2</xref>] 
This highlights the importance of improving the social
functioning and decreasing the relapse rate after an
acute episode of illness. A variety of approaches have
been tried, typically involving the use of antipsychotic
medication (to control positive psychotic symptoms) with adjunctive treatments such as psychotherapy, 
community-based interventions, family therapy, and so
forth.[<xref rid="B3" ref-type="bibr">3</xref>] One such adjunctive treatment for schizophrenia
is Naikan therapy, a structured method of self-reflection
which originated in Japan,[<xref rid="B4" ref-type="bibr">4</xref>] that has been shown
to produce short-term improvements in treatment
adherence and social function among patients with
schizophrenia in China.[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>] </p><p>This paper reports on a randomized controlled trial
of adjunctive treatment of schizophrenia with Naikan
therapy that assessed the psychiatric symptoms, social
functioning, and relapse rate of participants over a one-year
follow-up period.</p></sec><sec sec-type="methods" id="s7"><label>2.</label><title>Methods</title><sec id="s7a"><label>2.1</label><title>Subjects</title><p> 
As shown in Figure 1, among the 467 patients treated as
inpatients at the Shanghai Xuhui Mental Health Center from April 2013 to December 2013 there were 243
who met the following inclusion and exclusion criteria
for the study: a) meeting the diagnostic criteria of
schizophrenia specified in the International Classification
of Diseases-10, (ICD-10);[<xref rid="B8" ref-type="bibr">8</xref>] b) 18-60 years of age; c)
junior high school education or higher; d) inpatient
treatment results in a &#x02265;50% drop in the total score of
the Positive and Negative Syndrome Scale (PANSS)[<xref rid="B9" ref-type="bibr">9</xref>] or
a total PANSS score &#x02264;60 within 8 weeks of admission; d)
negative symptoms, agitation, and obsessive compulsive
symptoms are not severe enough to interfere with
study participation; e) no other mental disorder, organic
brain disorder, or substance use disorder; f) no severe
medical illness; g) not pregnant or breast-feeding; h) is
not participating in any other clinical trial; and i) both
the patient and the patient&#x02019;s guardian provide written
informed consent.</p><fig id="sap-27-04-220-g002.tiff" orientation="landscape" position="float"><label>Figure 1.</label><caption><title>Flowchart of the study</title></caption><graphic xlink:href="sap-27-04-220-g002"/></fig><p>
The PANSS was assessed on all potential participants
with schizophrenia every week after admission for eight
weeks and the individual was enrolled as soon as the total
PANSS score had decreased &#x02265;50% from baseline or was
&#x02264;60. The 243 enrolled patients were randomly assigned
to the intervention group (conventional antipsychotic
medication and rehabilitation therapy + Naikan therapy)
or the control group (conventional antipsychotic
medication and rehabilitation therapy) using a random
number generating function in the SPSS software.</p><p>
As shown in Figure 1, during the 4-week active
treatment phase of the study 2 patients who relapsed
dropped out of the intervention group while 5 patients
who relapsed and one who experienced a hypertensive
crisis dropped out of the control group. All participants
were hospitalized during this active treatment phase.
This left 123 patients in the intervention group and 111
in the control group who were then followed-up one
year later. The patients remained in hospital for varying
lengths of time after the end of the active treatment
(often determined by financial or family issues,not by
the clinical status of the patient), but all patients had
been discharged and were evaluated as outpatients at
the time of the one-year follow-up assessment.</p><p>
This study was approved by the Ethics Committee of
the Shanghai Xuhui Mental Health Center.</p></sec><sec id="s7b"><label>2.2</label><title>Intervention</title><p> 
All enrolled patients were treated with standard doses of
atypical antipsychotic medication by inpatient clinicians
who were blind to their group assignment. The dosage
employed at the time of enrollment (by which time the
PANSS had decreased &#x02265;50% from baseline or the total
PANSS score was &#x02264;60) was maintained throughout the
one-month intervention; the dosage was subsequently
adjusted by the treating clinician as needed during the
12-month follow-up period. All enrolled patients also
received routine rehabilitation therapy for inpatients, 
which included music therapy, biofeedback, cognitive
skills training, and so forth. Inpatients in the intervention
group received similar treatment except for the addition of Naikan therapy. After discharge from the hospital
all enrolled patients were seen monthly in the hospital
outpatient department by their treating clinician.</p><p>Naikan therapy,[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>] provided in 20 two-hour sessions
over a 4-week period, was conducted by three therapists
who had personally undergone Naikan therapy and
had received Naikan therapy training in Osaka, Japan.
Each session started with 15 minutes of consultation
with the patient in which the results of the previous
session were discussed and instructions and suggestions
for the current session were provided. After the
consultation, the patient completed the recommended
thought exercises while seated alone quietly in a room
specifically designed for Naikan therapy that was
separated into several individual cubicles by wooden
panels. The therapy involves systematically considering
and evaluating prior experiences from four perspectives:
three main themes, chronological stages, objects
(i.e., individuals), and procedures (i.e., assessing their
emotional responses). Patients consider three themes
based on their own experiences: &#x02018;what others did for
me&#x02019;, &#x02018;what I did for others&#x02019;, and &#x02018;what troubles I have
caused to others&#x02019;. They then review the recalled life
events in chronological order both from the perspective
of other participants in the events and from their own
perspective. This process is repeated for a range of
acquaintances, from the closest (e.g., parents, children, 
spouse) to the most distant (e.g., those whom the
individual dislikes the most). At each step in the process
the patient is encouraged to systematically analyze his
or her emotional responses such as feelings of regret, guilt, or gratitude, and the willingness to make amends.</p></sec><sec id="s7c"><label>2.3</label><title>Instruments</title><p>
The Chinese version of the Positive and Negative
Syndrome Scale (PANSS)[<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>] was used to evaluate the
severity of psychotic symptoms. It consists of four
subscales with 33 items and includes five factors:
positive, negative, cognitive, excitatory, and anxiety/depression factors. Items are rated 1 to 7 with higher
scores representing more severe symptoms.</p><p>The Personal and Social Performance scale (PSP)[<xref rid="B11" ref-type="bibr">11</xref>] 
is a single-item clinician rating from 0 to 100 used to
evaluate four components of social functioning: a) work
and study; b) social relationships; c) self-care; and d)
socially disruptive or aggressive behaviors. The score
is classified into 4 categories: 71 to 100 indicates no
difficulty or minor difficulty; 31 to 70 indicates definite
functional defect; and under 30 indicate poor social
function requiring active support and close monitoring.</p><p>The Insight and Treatment Attitude Questionnaire,
ITAQ[<xref rid="B12" ref-type="bibr">12</xref>] is an interviewer-completed questionnaire with
11 items scored 0 (none), 1 (partial insight), or 2 (definite
insight). The range in ITAQ total scores is from 0 to
22, with higher scores representing better insight and
greater willingness to adhere to recommended treatment;
the inter-rater reliability of the total score among raters
participating in this study was fair (Kappa=0.56).</p></sec><sec id="s7d"><label>2.4</label><title>Evaluation</title><p>
Four psychiatrists not involved in the treatment of the
patients who were blind to the group assignment of
patients were provided one week training in the use of
the scales and subsequently evaluated all patients at
baseline, after the 4-week intervention, and at the end
of the one-year follow-up. After training, the intra-class
correlation coefficient (ICC) assessing the inter-rater
reliability of the 4 clinicians for the total PANSS score
(0.74) and the total PSP score (0.63) were satisfactory.</p><p>Relapse during the 12-month period following
hospital discharge was defined as follows:[<xref rid="B13" ref-type="bibr">13</xref>] a) the
patient was re-hospitalized due to clinical deterioration, 
self-harm, or violent/destructive behavior; b) a
total PANSS score increase of &#x0003e;25%; c) a CGI clinical
change score of 6 or 7 (significant deterioration); or
d) the patient met diagnostic criteria of active phase
schizophrenia.</p></sec><sec id="s7e"><label>2.5</label><title>Statistical analysis</title><p>
Data were analyzed using SPSS 11.5. We conducted a
modified intention-to-treat (ITT) analysis of outcome
that included the 123 intervention group patients and
118 control group patients who completed the one-month
inpatient post-enrollment period (when the
intervention was administered to the intervention
group and the control group received routine inpatient
care) without relapsing or dropping out. For patients
who dropped out during the 1-year follow-up period, 
the last observed value carried forward (LOCF) method
was employed. Statistical tests appropriate to the
characteristics of the variable (i.e., dichotomous, ranked, 
or continuous) were conducted, including independent
and matched t-tests, chi-square tests and rank tests.
The main results between groups were assessed using repeated measures analysis of variance for unequal
time intervals between assessments. A p-value of &#x02264;0.05
was considered statistically significant.</p></sec></sec><sec id="s8"><label>3.</label><title>Results</title><p>
As shown in Table 1, there were no significant
differences between the two groups in demographic
characteristics, baseline illness characteristics, or family
history of mental illness.</p><table-wrap id="Table1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Comparison of the baseline characteristics of patients with schizophrenia in the intervention and
control groups</p></caption><table frame="hsides" rules="groups" style="text-align=center; "><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">intervention group<break/>(n=123)</th><th rowspan="1" colspan="1">control group<break/>(n=112)</th><th rowspan="1" colspan="1">statistic</th><th rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male, n (%)</td><td rowspan="1" colspan="1">63 (51.2%)</td><td rowspan="1" colspan="1">59 (52.7%)</td><td rowspan="1" colspan="1">X<sup>2</sup>=0.02</td><td rowspan="1" colspan="1">0.897</td></tr><tr><td align="left" rowspan="1" colspan="1">Age in years, mean (sd)</td><td rowspan="1" colspan="1">38.2 (10.5)</td><td rowspan="1" colspan="1">39.7 (9.8)</td><td rowspan="1" colspan="1"><italic>t</italic>=1.13</td><td rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" rowspan="1" colspan="1">Years of education, mean (sd)</td><td rowspan="1" colspan="1">10.2 (4.1)</td><td rowspan="1" colspan="1">9.8 (3.9)</td><td rowspan="1" colspan="1"><italic>t</italic>=0.76</td><td rowspan="1" colspan="1">0.445</td></tr><tr><td align="left" rowspan="1" colspan="1">Currently married, n (%)</td><td rowspan="1" colspan="1">67 (54.5%)</td><td rowspan="1" colspan="1">53 (47.3%)</td><td rowspan="1" colspan="1">X<sup>2</sup>=1.20</td><td rowspan="1" colspan="1">0.273</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at onset, mean (sd)</td><td rowspan="1" colspan="1">25.6 (4.9)</td><td rowspan="1" colspan="1">24.5 (6.7)</td><td rowspan="1" colspan="1">t =1.45</td><td rowspan="1" colspan="1">0.150</td></tr><tr><td align="left" rowspan="1" colspan="1">Years duration of illness, mean (sd)</td><td rowspan="1" colspan="1">13.7 (5.4)</td><td rowspan="1" colspan="1">14.9 (4.6)</td><td rowspan="1" colspan="1">t=1.82</td><td rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of hospitalizations, mean (sd)</td><td rowspan="1" colspan="1">2.5 (0.8)</td><td rowspan="1" colspan="1">2.3 (1.1)</td><td rowspan="1" colspan="1">Z=1.08</td><td rowspan="1" colspan="1">0.231</td></tr><tr><td align="left" rowspan="1" colspan="1">Months hospitalized, mean (sd)</td><td rowspan="1" colspan="1">4.8 (1.4)</td><td rowspan="1" colspan="1">4.7 (1.4)</td><td rowspan="1" colspan="1"><italic>t</italic>=0.39</td><td rowspan="1" colspan="1">0.585</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of schizophrenia, n (%)</td><td rowspan="1" colspan="1">13 (10.6%)</td><td rowspan="1" colspan="1">13 (11.6%)</td><td rowspan="1" colspan="1">X<sup>2</sup>=0.04</td><td rowspan="1" colspan="1">0.838</td></tr><tr><td align="left" rowspan="1" colspan="1">Days from index admission to recruitment for study, mean (sd)</td><td rowspan="1" colspan="1">25.5 (5.4)</td><td rowspan="1" colspan="1">26.0 (6.1)</td><td rowspan="1" colspan="1"><italic>t</italic>=0.64</td><td rowspan="1" colspan="1">0.516</td></tr></tbody></table></table-wrap><p>During the 12-month follow up, 13 (10.6%) of the
123 subjects in the intervention group experienced
relapses (all were re-hospitalized once) and 23 (20.5%)
of the 112 subjects in the control group experienced
relapses (two of them were re-hospitalized twice; 21
were re-hospitalized once (X<sup>2</sup>=4.50, <italic>p</italic>=0.034).</p><p>
Changes in the PANSS total score and 5 subscales
scores, PSP total score, and ITAP total score over the
three time periods (baseline, after 1-month intervention, 
and after 1-year follow-up) are shown in Figure 2 and
Table 2. The modified ITT repeated measures analysis
of variance results found no significant differences in
any of the 8 measures between the two groups at the
time of enrollment. The PANSS, PSP, and ITAQ total
scores all show significant main effects both for time
and for group and significant time*group interaction
effects. For all three measures the total scores improved
during the 1-month inpatient treatment following
recruitment, though the improvement in the PSP and
ITAQ total scores was greater in the intervention group
than in the control group (for PSP, <italic>t</italic>=2.72, <italic>p</italic>=0.007;
for ITAQ, <italic>t</italic>=2.83, <italic>p</italic>=0.005). Over the 12-month follow-up, 
the improvement in total scores after the 1-month
treatment was sustained or increased in the intervention
group, but in the control group the scores of the three
measures deteriorated. The significant time*group interaction effects for the three total scores show that
the improvement over time in the intervention group
was significantly greater than in the control group.</p><fig id="sap-27-04-220-g003.tiff" orientation="landscape" position="float"><label>Figure 2.</label><caption><title>Results of PANSS, PSP, and ITAQ total scores in patients with schizophrenia after acute symptoms
stabilized</title></caption><graphic xlink:href="sap-27-04-220-g003"/></fig><table-wrap id="Table2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>The result of repeated measures of analysis of variance of a modified intention-to-treat analysis of
Positive and Negative Syndrome Scale (PANSS) scores, Personal and Social Performance scale (PSP)
total score, and Insight and Treatment Attitude Questionnaire (ITAQ) total score of patients with
schizophrenia in the intervention and control groups</p></caption><table frame="hsides" rules="groups" style="text-align:center; "><thead><tr><th rowspan="2" colspan="1"/><th colspan="3" style="border-bottom:1px solid; " rowspan="1">intervention group (n=123)</th><th colspan="3" style="border-bottom:1px solid; " rowspan="1">control group (n=112)</th><th colspan="2" style="border-bottom:1px solid; " rowspan="1">time</th><th colspan="2" style="border-bottom:1px solid;" rowspan="1">group</th><th colspan="2" style="border-bottom:1px solid;" rowspan="1">time*group</th></tr><tr><th rowspan="1" colspan="1">at enrollment</th><th rowspan="1" colspan="1">at end of 1-month treatment</th><th rowspan="1" colspan="1">at 12 month follow-up</th><th rowspan="1" colspan="1">at enrollment</th><th rowspan="1" colspan="1">at end of 1-month treatment</th><th rowspan="1" colspan="1">at 12 month follow-up</th><th rowspan="1" colspan="1">F</th><th rowspan="1" colspan="1">p</th><th rowspan="1" colspan="1">F</th><th rowspan="1" colspan="1">p</th><th rowspan="1" colspan="1">F</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PANSS total score</td><td rowspan="1" colspan="1">51.8 (9.8)</td><td rowspan="1" colspan="1">45.5 (9.3)</td><td rowspan="1" colspan="1">43.0 (10.0)</td><td rowspan="1" colspan="1">52.1 (9.8)</td><td rowspan="1" colspan="1">44.1 (8.5)</td><td rowspan="1" colspan="1">48.6 (12.7)</td><td rowspan="1" colspan="1">9.73</td><td rowspan="1" colspan="1"><bold>0.003</bold></td><td rowspan="1" colspan="1">16.55</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">7.61</td><td rowspan="1" colspan="1"><bold>0.022</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;positive factor</td><td rowspan="1" colspan="1">11.0 (2.5)</td><td rowspan="1" colspan="1">9.3 (2.6)</td><td rowspan="1" colspan="1">9.9 (3.2)</td><td rowspan="1" colspan="1">11.1 (3.2)</td><td rowspan="1" colspan="1">9.1 (2.8)</td><td rowspan="1" colspan="1">10.4 (2.8)</td><td rowspan="1" colspan="1">8.24</td><td rowspan="1" colspan="1"><bold>0.013</bold></td><td rowspan="1" colspan="1">1.76</td><td rowspan="1" colspan="1">0.245</td><td rowspan="1" colspan="1">1.43</td><td rowspan="1" colspan="1">0.298</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;negative factor</td><td rowspan="1" colspan="1">12.9 (4.5)</td><td rowspan="1" colspan="1">10.6 (4.2)</td><td rowspan="1" colspan="1">9.2 (3.3)</td><td rowspan="1" colspan="1">13.3 (5.6)</td><td rowspan="1" colspan="1">11.8 (3.5)</td><td rowspan="1" colspan="1">12.0 (5.2)</td><td rowspan="1" colspan="1">6.59</td><td rowspan="1" colspan="1"><bold>0.036</bold></td><td rowspan="1" colspan="1">14.83</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">8.22</td><td rowspan="1" colspan="1"><bold>0.013</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;cognitive factor</td><td rowspan="1" colspan="1">9.8 (2.1)</td><td rowspan="1" colspan="1">9.2 (2.8)</td><td rowspan="1" colspan="1">9.5 (2.2)</td><td rowspan="1" colspan="1">9.9 (2.3)</td><td rowspan="1" colspan="1">9.2 (2.2)</td><td rowspan="1" colspan="1">9.6 (2.2)</td><td rowspan="1" colspan="1">8.09</td><td rowspan="1" colspan="1"><bold>0.017</bold></td><td rowspan="1" colspan="1">1.60</td><td rowspan="1" colspan="1">0.280</td><td rowspan="1" colspan="1">3.45</td><td rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;excitatory factor</td><td rowspan="1" colspan="1">10.0 (2.2)</td><td rowspan="1" colspan="1">8.9 (2.9)</td><td rowspan="1" colspan="1">8.2 (2.6)</td><td rowspan="1" colspan="1">9.7 (1.9)</td><td rowspan="1" colspan="1">8.8 (2.3)</td><td rowspan="1" colspan="1">9.2 (1.8)</td><td rowspan="1" colspan="1">15.17</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">1.83</td><td rowspan="1" colspan="1">0.193</td><td rowspan="1" colspan="1">7.96</td><td rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;anxiety/depression factor</td><td rowspan="1" colspan="1">8.5 (3.3)</td><td rowspan="1" colspan="1">7.8 (1.6)</td><td rowspan="1" colspan="1">6.8 (1.9)</td><td rowspan="1" colspan="1">8.3 (3.6)</td><td rowspan="1" colspan="1">7.4 (2.1)</td><td rowspan="1" colspan="1">7.7 (2.4)</td><td rowspan="1" colspan="1">10.33</td><td rowspan="1" colspan="1"><bold>&#x0003c; 0.001</bold></td><td rowspan="1" colspan="1">13.21</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">8.52</td><td rowspan="1" colspan="1"><bold>0.010</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">PSP total score</td><td rowspan="1" colspan="1">62.9 (7.8)</td><td rowspan="1" colspan="1">66.3 (9.1)</td><td rowspan="1" colspan="1">66.0 (9.2)</td><td rowspan="1" colspan="1">61.1 (7.4)</td><td rowspan="1" colspan="1">63.2 (8.4)</td><td rowspan="1" colspan="1">61.2 (7.5)</td><td rowspan="1" colspan="1">15.42</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">15.63</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">9.97</td><td rowspan="1" colspan="1"><bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">ITAQ total score</td><td rowspan="1" colspan="1">10.8 (4.3)</td><td rowspan="1" colspan="1">13.5 (5.1)</td><td rowspan="1" colspan="1">14.8 (5.8)</td><td rowspan="1" colspan="1">10.3 (4.0)</td><td rowspan="1" colspan="1">11.5 (5.4)</td><td rowspan="1" colspan="1">10.8 (5.8)</td><td rowspan="1" colspan="1">14.70</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">10.79</td><td rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td><td rowspan="1" colspan="1">8.44</td><td rowspan="1" colspan="1"><bold>0.011</bold></td></tr></tbody></table></table-wrap><p>Results for the 5 PANSS subscales are mixed. All
5 measures showed a significant main effect for time
but only 2 measures (i.e., negative factor and anxiety/depression factor) show a significant main effect
for group and only 3 measures (i.e., negative factor, 
excitatory factor, and anxiety/depression factor) have
a significant time*group interaction effect. As was the
case for the PANSS total score, all 5 subscale scores
improved in both groups during the 1-month inpatient treatment period. Over the 1-year follow-up period
there was a deterioration (compared to the result at
the end of the 1-month treatment) in all 5 measures
in the control group and in 2 of the 5 measures (the
positive factor and cognitive factor) in the intervention
group. The improvement in the other three measures-the positive, excitatory, and anxiety/depression PANSS
factors-was significantly greater in the intervention
group than in the control group.</p><p>The mean (sd) chlorpromazine-equivalent dosage
of antipsychotic medications in the intervention and
control groups at the time of recruitment were 217 (62) versus 214 (53) mg/d, respectively (<italic>t</italic>=0.40, <italic>p</italic>=0.691).
After 1 month of treatment the dosages were 213 (48)
versus 216 (57) mg/d, respectively (<italic>t</italic>=0.44, <italic>p</italic>=0.662).
After the 12-month follow-up period the dosages were
198 (40) versus 208 (45) mg/d, respectively (<italic>t</italic>=1.80, 
<italic>p</italic>=0.073). Compared to baseline, the mean dosage
had decreased significantly at the end of follow-up in
the intervention group (paired <italic>t</italic>=2.86, <italic>p</italic>=0.005) while
the change in dosage in the control group was not
statistically significant (<italic>t</italic>=0.91, <italic>p</italic>=0.362). Repeated
measures analysis of variance found that the main
effect for time was significant (<italic>F</italic>=15.36, p&#x0003c;0.001) but
the main effect for group was not significant (F=4.33, 
<italic>p</italic>=0.058) and the time*group interaction effect was
not significant (<italic>F</italic>=1.21, <italic>p</italic>=0.342). However, the effect
sizes of the intervention at recruitment, at the end of
1 month of treatment, and the end of the 12-month
follow-up were 0.0046, 0.056, and 0.28, respectively, 
which indicates a more pronounced downward trend
in the medication dosage in the intervention group
compared to that in the control group.</p></sec><sec id="s9"><label>4.</label><title>Discussion</title><sec id="s9a"><label>4.1</label><title>Main findings</title><p>
This relatively large, single blind, randomized controlled
trial found that a 1-month inpatient intervention of
daily Naikan therapy used as an adjunctive treatment
for schizophrenia (after active symptoms have been
effectively treated using antipsychotic medication)
can reduce psychotic symptoms (particularly negative
symptoms), improve social functioning, enhance
insight and-most importantly-significantly reduce
re-hospitalization over a one-year period. This result
confirms the findings of earlier studies that used smaller
samples and followed patients for shorter periods of
time.[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>] We also found that one year after completing
the intervention the dosage of antipsychotic medication
used by patients provided Naikan therapy was lower
than that of patients receiving standard treatment;
but this result was not as robust as that for the change
in symptoms, so further research will be needed to
confirm this difference.</p><p>Naikan therapy was developed as a psychological
treatment in Japan by Yoshimoto Inobu in 1953 based
on Oriental culture.[<xref rid="B4" ref-type="bibr">4</xref>] The basic tenet that individuals
can control their own emotional responses and
behaviors through self-directed cognitive exercises is
consistent with the Chinese world view, so this therapy
has become increasingly popular in clinical settings in
China.[<xref rid="B14" ref-type="bibr">14</xref>] However, the mechanism of action of Naikan
therapy remains uncertain. The intense focus the
therapy places on improving interpersonal relationships
and on self-examination of one&#x02019;s own role in problematic
relationships or experiences may help patients decrease
their self-centeredness, improve their insight about
their illness, and enhance their engagement in the social
world.[<xref rid="B15" ref-type="bibr">15</xref>] The reasons for relapse in schizophrenia are still being debated by specialists,[<xref rid="B16" ref-type="bibr">16</xref>] but there is general
agreement that relapse is primarily caused by poor drug
adherence, poor family relationships, residual psychotic
symptoms, and lack of insight.[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>] The reduced relapse
rates seen when adjunctive Naikan therapy is provided
to patients with schizophrenia who have recovered from
an acute episode of illness is most probably related to
the sustained remission of active psychotic symptoms, 
improved insight (and, thus, medication adherence), 
and better social functioning of patients receiving
Naikan therapy compared to those receiving standard
treatment.</p></sec><sec id="s9b"><label>4.2</label><title>Limitations</title><p>
There are several issues that need to be considered
when interpreting these results: a) Patients in this study
were all inpatients at a single psychiatric hospital and
they had all completed junior high school. It is uncertain
whether or not Naikan therapy would be effective for
a less selective group of individuals with schizophrenia
or for those with lower levels of education. b) As
employed in this study, Naikan therapy is an intensive
daily intervention that continues for one month and is
provided to inpatients after their acute symptoms have
resolved using antipsychotic medication. It is unknown
whether or not this therapy would be effective if
administered on an outpatient basis or on a less
intensive schedule. c) We used a modified ITT analysis
that excluded 2 patients from the intervention group
who relapsed during the 1-month intervention and
5 patients from the control group who relapsed (and
1 that had a hypertensive crisis) during the 1-month
following recruitment. We excluded these individuals
so the results would assess the long-term effects of
persons who completed the Naikan intervention.
Using a more standard ITT analysis that included these
dropout patients would have made the overall results
stronger than those we reported (because more patients relapsed during the first month of treatment
in the control group than in the intervention group). d)
The assessment of social function in the study using the
PSP-including items about family function and work
function-is not well-suited to assessing inpatients, so
the use of this measure at baseline and at the end of
the 1-month intervention (when the participants were
hospitalized) may have been biased. 3) The assessment
of medication adherence was primarily based on
patient and family self-reports, so it may not have been
accurate. e) The 12-month follow-up period is longer
than that used in many studies, but it remains unclear
how long the effect of Naikan therapy persists: does one
treatment episode have a permanent beneficial effect
or is there a need for regular booster sessions?</p></sec><sec id="s9c"><label>4.3</label><title>Implication</title><p>
This study provides robust support for the beneficial
effects of using adjunctive Naikan therapy in the rehabilitative treatment of Chinese patients who have
recovered from an acute episode of schizophrenia.
However, the sample was quite selective so further
research will be needed to confirm the results in
outpatients, in patients with lower levels of education, 
and in patients from different parts of China. Further
work is also needed to assess the optional duration, 
intensity, and interval between booster sessions. Data
from larger samples could be used to identify the
demographic and clinical factors that predict favorable
outcome from Naikan therapy and, thus, would help
characterize the patients that should preferentially
be provided with this treatment. Finally, standardized
methods of training clinicians to provide Naikan therapy
will be needed before this treatment can be widely
employed in China or elsewhere.</p></sec></sec></body><back><fn-group><fn><p>Conflict of interest: The authors report no conflict of interest related to this
manuscript.</p></fn></fn-group><fn-group><fn><p>Ethics approval: The study was approved by the research review
committee of Shanghai Mental Health Center of Xuhui
district.</p></fn></fn-group><fn-group><fn><p>Informed consent: Written informed consent was obtained from all
participants and their guardians before the study.</p></fn></fn-group><bio id="d35e38"><p><graphic xlink:href="sap-27-04-220-g001.gif" position="float" orientation="portrait"/></p><p>Zhang Hong, an associate chief physician, graduated from Tongji University Medical School in 1995.
She has been working in the psychiatric department of the Shanghai Xuhui Mental Health Center
since 2001 and is currently the head of the medical department and a ward director at the hospital.
Her current research activities focus on the rehabilitation and treatment of mental disorders.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>PX</given-names></name><name><surname>Tang</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>[Awareness to the risk factors of relapse in schizophrenia]</article-title><source>Zhongguo Xin Li Wei Sheng Za Zhi</source><year>2004</year><volume>18</volume><issue>4</issue><fpage>264</fpage><lpage>268</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3321/j.issn:1000-6729.2004.04.019</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascher-Svanum</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Faries</surname><given-names>DE</given-names></name><name><surname>Salkever</surname><given-names>D</given-names></name><name><surname>Slade</surname><given-names>EP</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><etal/></person-group><article-title>The cost of relapse and the predictors of relapse in the treatment of schizophrenia</article-title><source>BMC Psychiatry</source><year>2010</year><volume>10</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-10-2</pub-id><pub-id pub-id-type="pmid">20059765</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Morita therapy for schizophrenia</article-title><source>Schizophr Bull</source><year>2008</year><volume>34</volume><issue>6</issue><fpage>1021</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbn124</pub-id><pub-id pub-id-type="pmid">18852234</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa-de</surname><given-names>Silva C</given-names></name></person-group><article-title>Demystifying Japanese therapy: ananalysis of Naikan and the Ajase Complex through Buddhist thought</article-title><source>Ethos</source><year>2007</year><volume>35</volume><issue>4</issue><fpage>411</fpage><lpage>444</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>XT</given-names></name><name><surname>Mao</surname><given-names>FQ</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>JY</given-names></name><etal/></person-group><article-title>[Study of Naikan cognitive therapy to improve the social function during rehabilitation of schizophrenia]</article-title><source>Tianjin Yi Ke Da Xue Xue Bao</source><year>2014</year><volume>20</volume><issue>4</issue><fpage>313</fpage><lpage>315</lpage><comment>Chinese</comment></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name></person-group><article-title>[A study of Naikan therapy in the treatment of social function rehabilitation for schizophrenia]</article-title><source>Lin Chuang Jing Shen Yi Xue Za Zhi</source><year>2010</year><volume>20</volume><issue>1</issue><fpage>58</fpage><lpage>59</lpage><comment>Chinese</comment></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>RJ</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>ZW</given-names></name><name><surname>Huang</surname><given-names>YP</given-names></name><name><surname>Jie</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>BH</given-names></name><etal/></person-group><article-title>[Effect of Naikan therapy and behavioral therapy on recent medication adherence in schizophrenic patients]</article-title><source>Lin Chuang Jing Shen Yi Xue Za Zhi</source><year>2014</year><volume>24</volume><issue>4</issue><fpage>214</fpage><lpage>219</lpage><comment>Chinese</comment></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="book"><collab>World Health Organization</collab><person-group person-group-type="translator"><name><surname>Fan</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>XD</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><source>[ICD-10 Classification of Mental andBehavioral Disorders (Clinical Description and Diagnosis)]</source><publisher-loc>Beijing</publisher-loc><publisher-name>People's Health Publishing House</publisher-name><year>1993</year><fpage>72</fpage><lpage>80</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.1097/MCD.0b013e32832e38a6</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MY</given-names></name><etal/></person-group><source>[Psychiatric Rating Scale Manual, 2nd edition]</source><publisher-loc>Changsha</publisher-loc><publisher-name>Hunan Science and Technology Press</publisher-name><year>1998</year><fpage>150</fpage><lpage>153</lpage><comment>Chinese</comment></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name></person-group><article-title>[The Chinese norm and factor analysis of PANSS]</article-title><source>Zhongguo Lin Chuang Xin Li Xue Za Zhi</source><year>2000</year><volume>8</volume><issue>2</issue><fpage>65</fpage><lpage>69</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3969/j.issn.1005-3611.2000.02.001</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>TM</given-names></name><name><surname>Shu</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>CH</given-names></name><name><surname>Su</surname><given-names>YA</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>[Evaluation of reliability and validity of the Chinese version of personal and social performance scale in patients with schizophrenia]</article-title><source>Zhongguo Xin Li Wei Sheng Za Zhi</source><year>2009</year><volume>23</volume><issue>11</issue><fpage>790</fpage><lpage>793</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3969/j.issn.1000-6729.2009.11.008</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HQ</given-names></name><name><surname>Zhang</surname><given-names>PY</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>PD</given-names></name><name><surname>Wu</surname><given-names>HW</given-names></name></person-group><article-title>[Schizophrenia insight: "Application of the insight and treatment attitude questionnaire"]</article-title><source>Shanghai Arch Psychiatry</source><year>1995</year><volume>7</volume><fpage>158</fpage><lpage>161</lpage><comment>Chinese</comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csernansky</surname><given-names>JG</given-names></name><name><surname>Mahmoud</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>R</given-names></name></person-group><article-title>A comparison of risperidone and haloperidol for the prevention of relapse inpatients with schizophrenia</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa002028</pub-id><pub-id pub-id-type="pmid">11777998</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YB</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name></person-group><article-title>[Application and developmentof Naikan therapy]</article-title><source>Lin Chuang Jing Shen Yi Xue Za Zhi</source><year>2010</year><volume>20</volume><issue>1</issue><fpage>61</fpage><lpage>63</lpage><comment>Chinese</comment></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>ZT</given-names></name></person-group><article-title>[NaiKan therapy]</article-title><source>Jian Kang Xin Li Xue</source><year>1996</year><volume>4</volume><fpage>10</fpage><lpage>11</lpage><comment>Chinese</comment></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San</surname><given-names>L</given-names></name><name><surname>Bernardo</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>A</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>M</given-names></name></person-group><article-title>Factors associated with relapse in patients with schizophrenia</article-title><source>Int J Psychiatry Clin Pract</source><year>2013</year><volume>17</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3109/13651501.2012.687452</pub-id><pub-id pub-id-type="pmid">22731397</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivares</surname><given-names>J M</given-names></name><name><surname>Sermon</surname><given-names>J</given-names></name><name><surname>Hemels</surname><given-names>M</given-names></name><name><surname>Schreiner</surname><given-names>A</given-names></name></person-group><article-title>Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review</article-title><source>Ann Gen Psychiatry</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1744-859X-12-32</pub-id><pub-id pub-id-type="pmid">24148707</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>WF</given-names></name><name><surname>Zou</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>ZM</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><etal/></person-group><article-title>[Compliance with antipsychotic treatment and relapse in schizophrenia]</article-title><source>Zhong Hua Jing Shen Ke Za Zhi</source><year>2012</year><volume>45</volume><fpage>25</fpage><lpage>28</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3760/cma.j.issn.1006-7884.2012.01.011</pub-id></element-citation></ref></ref-list></back></article>